Journal of Dispersion Science and Technology,
Journal Year:
2024,
Volume and Issue:
45(12), P. 2249 - 2264
Published: May 5, 2024
Isoniazid
(INH)
is
amongst
the
first-line
antibiotics
that
have
been
employed
for
treatment
of
Tuberculosis
(TB).
Despite
its
potent
anti-tubercular
action,
susceptibility
to
rapid
hepatic
first-pass
metabolism
and
elimination
largely
limits
oral
bioavailability,
has
associated
with
induction
drug
resistance
adverse
effects.
This
presents
study
aims
at
development
evaluation
unique
mannosylated
INH
loaded
solid
lipid
nanoparticles
(Mn-INH-SLNs)
TB.
The
Mn-INH-SLNs
demonstrated
a
particle
size
466
±
11
nm,
which
was
acceptable
macrophage
targeting
had
%
entrapment
efficiency
80.41
1.37%
(n
=
6).
dissolution
studies
depicted
dual-phase
release
profile,
i.e.,
burst
followed
by
sustained
release,
revealing
best
fit
Korsmeyer-Peppas
model.
MTT
assay
(cytotoxicity
study)
performed
utilizing
J774A.1
cells
optimized
deemed
them
be
safe
nontoxic.
Mannosylated
SLNs
tagged
coumarin-6
(C6
–
an
established
fluorescent
marker)
showed
substantially
high
intracellular
internalization
(1.11-folds)
when
analyzed
through
flow
cytometric
analysis
(FACS).
in
vivo
pharmacokinetic
following
per-oral
administration
rats
significant
rise
relative
bioavailability
(∼5.5-folds)
compared
pure
solution.
bio-distribution
(drug
disposition)
exhibited
greater
lung
accumulation
(2.13-folds)
comparison
unconjugated
INH-SLNs
(Un-INH-SLNs).
promising
results
depict
targeted-optimized
may
propitious
tool
fight
Nano Letters,
Journal Year:
2024,
Volume and Issue:
24(25), P. 7629 - 7636
Published: June 14, 2024
Vaccination
for
cancers
arising
from
human
papillomavirus
(HPV)
infection
holds
immense
potential,
yet
clinical
success
has
been
elusive.
Herein,
we
describe
vaccination
studies
involving
spherical
nucleic
acids
(SNAs)
incorporating
a
CpG
adjuvant
and
peptide
antigen
(E711–19)
the
HPV-E7
oncoprotein.
Administering
vaccine
to
humanized
mice
induced
immunity-dependent
on
oligonucleotide
anchor
chemistry
(cholesterol
vs
(C12)9).
SNAs
containing
(C12)9-anchor
enhanced
IFN-γ
production
>200-fold,
doubled
memory
CD8+
T-cell
formation,
delivered
more
than
twice
amount
of
lymph
nodes
in
vivo
compared
simple
admixture.
Importantly,
analogous
construct
with
weaker
cholesterol
performed
similar
admix.
Moreover,
(C12)9-SNAs
activated
50%
dendritic
cells
generated
T-cells
cytotoxic
toward
an
HPV+
cancer
cell
line,
UM-SCC-104,
near
2-fold
greater
efficiency.
These
observations
highlight
pivotal
role
structural
design,
specifically
anchoring
strength
(which
correlates
overall
stability),
developing
efficacious
therapeutic
vaccines.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 5, 2025
The
incidence
and
mortality
rates
of
digestive
tract
tumors,
especially
gastric
colorectal
cancers,
are
high
worldwide.
Owing
to
their
unique
advantages,
such
as
efficient
drug
loading,
safety,
targeting
properties,
nanoparticles
(NPs)
have
demonstrated
great
potential
in
the
treatment
gastrointestinal
tumors.
However,
practical
application
is
limited
by
several
factors,
costs,
few
clinical
trials,
long
approval
periods.
In
this
review,
we
summarize
three
types
immunotherapeutic
nanomaterial
drugs
for
tumors:
organic,
inorganic,
hybrid
nanomaterials.
This
article
also
discusses
current
status
research
development
field
advantages
each
type
material
provide
theoretical
references
developing
new
advancing
research.
BIO Integration,
Journal Year:
2025,
Volume and Issue:
6(1)
Published: Jan. 1, 2025
Lipid-based
Nanoparticles
(LBNPs)
have
emerged
as
a
transformative
approach
in
cancer
treatment,
offering
innovative
drug
delivery
solutions
that
enhance
therapeutic
efficacy
while
minimizing
adverse
effects.
By
exploring
the
characterization,
classification,
synthesis,
targeting
strategies,
and
advantages
of
LBNPs,
this
study
highlights
how
LBNPs
been
used
to
overcome
limitations
traditional
chemotherapy
improve
patient
outcomes.
As
nanotechnology
revolutionizes
therapy,
emergence
promising
strategy
for
targeted
has
led
optimism
regarding
future
treatment.
This
review
extensively
assesses
structure,
categories,
production
methods,
benefits,
recent
advancements
treating
cancer.
It
also
current
challenges
possible
directions.
is
aimed
at
providing
comprehensive
understanding
LBNPs’
potential
therapy.
Liposomes,
nanostructured
lipid
carriers,
solid
nanoparticles,
lipid-polymer
hybrid
nanoparticles
are
all
types
each
with
unique
features
interest
These
particles
can
be
synthesized
through
various
procedures,
such
bulk
nanoprecipitation,
solvent-based
emulsification,
or
microfluidics.
Passive
systems,
active
responsive
platforms
direct
tumors.
Consequently,
provide
an
improved
release
pattern
minimizes
side
effects
enhancing
efficacy.
With
combination
offer
hopeful
Continued
research
expected
outcomes
overall
quality
life
care.
ACS Nano,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 7, 2025
Nanoparticles
(NPs)
have
been
extensively
researched
for
targeted
diagnostic
imaging
and
drug
delivery,
yet
their
clinical
translation
remains
limited,
with
only
a
few
achieving
Food
Drug
Administration
approval.
This
limited
success
is
primarily
due
to
challenges
in
precise
organ-
or
tissue-specific
targeting,
which
arise
from
off-target
tissue
accumulation
suboptimal
clearance
profiles.
Herein
we
examine
the
critical
role
of
physicochemical
properties,
including
size,
surface
charge,
shape,
elasticity,
hardness,
density,
governing
biodistribution,
targetability,
NPs.
We
highlight
recent
advancements
engineering
NPs
showcasing
both
significant
progress
remaining
field
nanomedicine.
Additionally,
discuss
emerging
tools
technologies
that
are
being
developed
address
these
challenges.
Based
on
insights
materials
science,
biomedical
engineering,
computational
biology,
research,
propose
key
design
considerations
next-generation
nanomedicines
enhanced
organ
selectivity.
Drug Delivery and Translational Research,
Journal Year:
2022,
Volume and Issue:
12(9), P. 2042 - 2047
Published: July 30, 2022
Abstract
Nanotechnologies
enable
great
opportunities
for
the
development
and
use
of
innovative
(nano)medicine
s
.
As
is
common
scientific
technical
developments,
recognized
safety
evaluation
methods
regulatory
purposes
are
lagging
behind.
The
specific
properties
responsible
desired
functioning
also
hamper
such
products.
Pharmacokinetics
determination
active
pharmaceutical
ingredient
as
well
nanomaterial
component
crucial.
Due
to
their
particulate
nature,
nanomedicines,
similar
all
nanomaterials,
primarily
removed
from
circulation
by
phagocytizing
cells
that
part
immune
system.
Therefore,
system
can
be
potentially
a
target
adverse
effects
thus
needs
special
attention
during
evaluation.
This
DDTR
issue
on
results
REFINE
project
science
framework
nanomedical
products
presents
highly
valuable
body
knowledge
needed
address
challenges
gaps
in
currently
available
testing
nanomedicines.
Biomaterials Research,
Journal Year:
2024,
Volume and Issue:
28
Published: Jan. 1, 2024
Identification
of
metastatic
lymph
nodes
is
a
crucial
step
in
node
dissection
to
prevent
further
cancer
spread
and
recurrence.
However,
the
current
limitations
detection
often
result
extensive
resection
normal
nodes,
leading
serious
complications.
The
clinical
application
indocyanine
green
(ICG)
as
tool
for
challenging
because
its
short
plasma
half-life
rapid
light-induced
decomposition
clearance.
To
overcome
this
limitation,
we
used
polydopamine
nanoparticles
(PNs)
carriers
ICG
screened
optimal
particle
size
detecting
nodes.
ICG/PNs
with
sizes
80,
160,
300,
600
nm
were
synthesized,
their
loading
efficiency,
physical
stability,
distribution
evaluated.
absorbed
on
PNs
was
found
be
protected
from
light
degradation,
retention
at
improved.
Notably,
favored
fluorescence
signal
compared
nonmetastatic
Among
tested
sizes,
80-nm
ICG/PN
showed
higher
This
study
suggests
that
potentially
valuable
reagent
diagnosis
metastasis.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(5), P. 609 - 609
Published: May 4, 2025
The
oral
delivery
of
DNA/RNA
nanoparticles
represents
a
transformative
approach
in
immunotherapy
and
vaccine
development.
These
enable
targeted
immune
modulation
by
delivering
genetic
material
to
specific
cells
the
gut-associated
system,
triggering
both
mucosal
systemic
responses.
Unlike
parenteral
administration,
route
offers
unique
immunological
environment
that
supports
tolerance
activation,
depending
on
formulation
design.
This
review
explores
underlying
mechanisms
nanoparticles,
their
design
strategies,
recent
advances
application.
Emphasis
is
placed
strategies
overcome
physiological
barriers
such
as
acidic
pH,
enzymatic
degradation,
mucus
entrapment,
epithelial
tight
junctions.
Special
attention
given
role
lymphoid
tissue
mediating
responses
therapeutic
potential
these
systems
platforms,
food
allergies,
autoimmune
diseases,
chronic
inflammation.
Despite
challenges,
nanoparticle
support
translation
technologies
into
clinical
applications
for
immunomodulation
vaccination.
Pharmacological Reviews,
Journal Year:
2024,
Volume and Issue:
76(6), P. 1326 - 1398
Published: Aug. 23, 2024
Historically,
the
intestinal
lymphatics
were
considered
passive
conduits
for
fluids,
immune
cells,
dietary
lipids,
lipid
soluble
vitamins
and
lipophilic
drugs.
Studies
of
lymphatic
drug
delivery
in
late
20th
century
focussed
primarily
on
physicochemical
properties,
especially
high
lipophilicity,
that
resulted
transport.
More
recent
discoveries
have
changed
our
traditional
view
by
demonstrating
are
active,
plastic
tissue-specific
players
a
range
biological
pathological
processes,
including
within
intestine.
These
findings
have,
turn,
inspired
exploration
lymph-specific
therapies
diseases,
as
well
development
more
sophisticated
strategies
to
actively
deliver
drugs
or
vaccines
lymph,
nanotechnologies,
prodrugs
lipid-conjugated
materials
9hitchhike9
transport
pathways.
With
increasing
novel
therapeutics
there
has
been
interest
whether
these
absorbed
transported
through
lymph
after
oral
administration.
Here
we
review
current
state
understanding
anatomy
physiology
gastrointestinal
system
health
disease,
with
focus
aspects
relevant
delivery.
We
summarise
state-of-the-art
approaches
quantify
their
uptake
into
system.
Finally,
excitingly,
discuss
examples
significant
pharmacokinetic
therapeutic
benefits
achieved
via
also
propose
advance
clinical
application
future.
Significance
Statement
This
comprehensive
details
It
highlights
shift
toward
use
achieve
patients.
